Hutchins Elizabeth, Shaikh Kashif, Kinninger April, Cherukuri Lavanya, Birudaraju Divya, Mao Song Shou, Nakanishi Rine, Almeida Shone, Jayawardena Eranthi, Shekar Chandana, Flores Fredinand, Hamal Sajad, Sheikh Salman, Johanis Amit, Cu Benedict, Trad George, Budoff Matthew J
Los Angeles Biomedical Institute at Harbor-UCLA Medical Institute, Torrance, CA 90502, USA.
Exp Ther Med. 2020 Feb;19(2):1468-1471. doi: 10.3892/etm.2019.8373. Epub 2019 Dec 27.
Increased left ventricular myocardial mass (LVM) is a well known prognostic marker of poor cardiac outcomes. Decreases in LVM have been shown to decrease the cardiovascular risk. Aged garlic extract (AGE) has been shown to have an overall favorable effect on cardiac health; however, to the best of our knowledge, no study to date has specifically examined its effects on left ventricular mass. This study investigated whether AGE can affect LVM measured by cardiac computed tomography angiography (CCTA) in patients with diabetes mellitus (DM). This is a double-blind, placebo controlled randomized trial. In total, 65 participants with DM with a mean age of 58 years were prospectively assigned to consume 2,400 mg AGE/day or the placebo orally. Both groups underwent CCTA at baseline and follow-up at 1 year apart. LVM was measured using automated software. The baseline characteristics did not differ between the AGE and placebo groups. There was a trend towards a significant reduction in LVM at follow-up as compared to baseline in the AGE group (119.30±34.77 vs. 121.0±34.70, P=0.059). No change was observed in LVM in the placebo group at 1-year follow-up as compared to baseline (124.6±37.33 vs. 124.6±35.13, P=0.9). On the whole, this study indicated that AGE may decrease or stabilize LVM. Further studies however, with a larger sample size and longer follow-up times are required to evaluate the effects of AGE on hypertension and LVM.
左心室心肌质量(LVM)增加是心脏不良预后的一个众所周知的预测指标。已证实LVM降低可降低心血管风险。老年大蒜提取物(AGE)已被证明对心脏健康具有总体有益作用;然而,据我们所知,迄今为止尚无研究专门考察其对左心室质量的影响。本研究调查了AGE是否会影响糖尿病(DM)患者通过心脏计算机断层扫描血管造影(CCTA)测量的LVM。这是一项双盲、安慰剂对照的随机试验。总共65名平均年龄为58岁的DM患者被前瞻性地分配为每日口服2400毫克AGE或安慰剂。两组在基线时以及相隔1年的随访时均接受CCTA检查。使用自动化软件测量LVM。AGE组和安慰剂组的基线特征无差异。与基线相比,AGE组随访时LVM有显著降低的趋势(119.30±34.77 vs. 121.0±34.70,P = 0.059)。与基线相比,安慰剂组在1年随访时LVM未观察到变化(124.6±37.33 vs. 124.6±35.13,P = 0.9)。总体而言,本研究表明AGE可能会降低或稳定LVM。然而,需要进一步开展样本量更大、随访时间更长的研究来评估AGE对高血压和LVM的影响。